文献速递白血病淋巴瘤浆细胞疾病

一种新型CXCR4拮抗剂IgG1抗体(PF-06747143)用于治疗血液系统恶性肿瘤

A novel CXCR4 antagonist IgG1 antibody (PF-06747143) for the treatment of hematologic malignancies.
PubMed 文献 · Blood Adv · 2017-06-21

本文报告了一种人源化CXCR4 IgG1抗体PF-06747143的临床前研究。该抗体可抑制CXCL12介导的信号通路与细胞迁移,在体内模型中快速短暂动员骨髓细胞至外周血,并通过Fc恒定区介导的效应功能诱导肿瘤细胞死亡。PF-06747143在非霍奇金淋巴瘤、急性髓系白血病和多发性骨髓瘤模型中显示强抗肿瘤效果,并与标准化疗药物协同,目前正在进行1期临床试验(NCT02954653)。

要点

  • PF-06747143是一种人源化CXCR4 IgG1抗体,可抑制CXCL12介导的信号通路和细胞迁移。
  • 在体内临床前研究中,PF-06747143单药快速、短暂地将细胞从骨髓动员至外周血。
  • PF-06747143通过Fc恒定区介导的效应功能诱导肿瘤细胞死亡,并在多个血液肿瘤模型中显示抗肿瘤效果。

核心结论

  • PF-06747143是一种潜在的最佳同类抗CXCR4拮抗剂,用于治疗血液系统恶性肿瘤,包括耐药情况。

研究设计与样本

  • 临床前研究:开发人源化CXCR4 IgG1抗体PF-06747143,在体内临床前研究和多种血液肿瘤模型中评估其作用。

主要发现

  • PF-06747143单药在体内临床前研究中快速且短暂地将细胞从骨髓动员至外周血。
  • PF-06747143通过Fc恒定区介导的效应功能有效诱导肿瘤细胞死亡;与无Fc效应功能的IgG4版本抗体相比,Fc介导的细胞杀伤机制不仅增强抗肿瘤疗效,还缩短细胞动员持续时间。
  • PF-06747143在非霍奇金淋巴瘤、急性髓系白血病和多发性骨髓瘤等多种血液肿瘤模型中显示强抗肿瘤效果。
  • 在化疗耐药的急性髓系白血病患者来源异种移植模型和多发性骨髓瘤模型中,PF-06747143与标准化疗药物协同作用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The chemokine receptor CXCR4 is highly expressed and associated with poor prognosis in multiple malignancies. Upon engagement by its ligand, CXCL12, CXCR4 triggers intracellular signaling pathways that control trafficking of cells to tissues where the ligand is expressed, such as the bone marrow (BM). In hematologic cancers, CXCR4-driven homing of malignant cells to the BM protective niche is a key mechanism driving disease and therapy resistance. We developed a humanized CXCR4 immunoglobulin G1 (IgG1) antibody (Ab), PF-06747143, which binds to CXCR4 and inhibits CXCL12-mediated signaling pathways, as well as cell migration. In in vivo preclinical studies, PF-06747143 monotherapy rapidly and transiently mobilized cells from the BM into the peripheral blood. In addition, PF-06747143 effectively induced tumor cell death via its Fc constant region-mediated effector function. This Fc-mediated cell killing mechanism not only enhanced antitumor efficacy, but also played a role in reducing the duration of cell mobilization, when compared with an IgG4 version of the Ab, which does not have Fc-effector function. PF-06747143 treatment showed strong antitumor effect in multiple hematologic tumor models including non-Hodgkin lymphoma (NHL), acute myeloid leukemia (AML), and multiple myeloma (MM). Importantly, PF-06747143 synergized with standard-of-care agents in a chemoresistant AML patient-derived xenograft model and in an MM model. These findings suggest that PF-06747143 is a potential best-in-class anti-CXCR4 antagonist for the treatment of hematologic malignancies, including in the resistant setting. PF-06747143 is currently in phase 1 clinical trial evaluation (registered at www.clinicaltrials.gov as #NCT02954653).

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Liu SH, Gu Y, Pascual B, et al. A novel CXCR4 antagonist IgG1 antibody (PF-06747143) for the treatment of hematologic malignancies. Blood Adv. 2017. PMID: 29296751. doi:10.1182/bloodadvances.2016003921

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。